Search in:

Expert Review of Clinical Immunology Volume 12, 2016 - Issue 1

Submit an article Journal homepage

Free access

4,550

Views

CrossRef citations to date

Altmetric

Editorials

Interleukin 17-A inhibition in the treatment of psoriasis

Zenas ZN YiuDermatology Centre, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UKView further author information

Christopher EM GriffithsDermatology Centre, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UKCorrespondence[email protected]
View further author information

Pages 1-4 | Published online: 11 Nov 2015

Cite this article
https://doi.org/10.1586/1744666X.2016.1112739
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions
View PDF PDF

References

Papers of special note have been highlighted as:
Google Scholar
* Of interest
Google Scholar
** Of considerable interest
Google Scholar
Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386:541–551. Epub 2015 Jun 15.
Web of Science ®Google Scholar

* This paper reported the results of two phase III randomized controlled trials (UNCOVER-2 and UNCOVER-3), showing the superior efficacy of ixekizumab against etanercept for the treatment of psoriasis at both the primary endpoint of PASI 75 and PASI 90 at week 12.

Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181–1189. Epub 2012 Mar 30.
PubMed Web of Science ®Google Scholar
Lebwohl M, Strober B, Menter A, et al. Phase 3 Studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328. Epub 2015 Oct 01.
PubMed Web of Science ®Google Scholar

** This paper reported the results from two phase III clinical trials, AMAGINE-2 and AMAGINE-3, showing brodalumab to have a higher efficacy than ustekinumab for the treatment of psoriasis, using a stringent primary endpoint of PASI 100 at week 12.

Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128(5):1207–1211. Epub 2008 Jan 18.
PubMed Web of Science ®Google Scholar
Griffiths CE, Strober BE, Van De Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118–128. Epub 2010 Jan 15.
PubMed Web of Science ®Google Scholar
Warren RB, Smith CH, Yiu ZZ, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015; Epub 2015 Jun 09.
Web of Science ®Google Scholar
Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. Epub 2014 Jul 10.
PubMed Web of Science ®Google Scholar
Papp K, Reich K, Leonardi C, et al. Efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis: results of AMAGINE-1, a phase 3, randomized, double-blind, placebo-controlled study through week 12. J Am Acad Dermatol. 2015;72(5, Supplement 1):AB233.
Web of Science ®Google Scholar
Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereology: JEADV. 2015;29(4):645–648. Epub 2014 Nov 06.
PubMed Web of Science ®Google Scholar
Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73:400–409. Epub 2015 Jun 21.
Google Scholar

** This study, reporting results from the CLEAR randomized controlled trial, showed that secukinumab was superior in efficacy to ustekinumab for the treatment of psoriasis using a primary endpoint of PASI 90 at week 16.

Garcia-Doval I, Carretero G, Vanaclocha F, et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol. 2012;148(4):463–470. Epub 2012 Apr 18.
PubMed Web of Science ®Google Scholar
Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460–1468. Epub 2011 Apr 14.
PubMed Web of Science ®Google Scholar
Menting SP, Coussens E, Pouw MF, et al. Developing a therapeutic range of adalimumab serum concentrations in management of psoriasis: a step toward personalized treatment. JAMA Dermatol. 2015;151(6):616–622. Epub 2015 Mar 26.
PubMed Web of Science ®Google Scholar
Bendtzen K. Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists. Discov Med. 2013;15(83):201–211. Epub 2013 May 03.
PubMed Web of Science ®Google Scholar
Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–1700. Epub 2012 May 19.
PubMed Web of Science ®Google Scholar
Amgen. Amgen to terminate participation in co-development and commercialization of brodalumab. Amgen; [ cited 2015 Jul 15]; Available from: http://wwwext.amgen.com/media/media_pr_detail.jsp?year=2015&releaseID=2052862.
Google Scholar
Kaltsonoudis E, Voulgari PV, Konitsiotis S, et al. Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev. 2014;13(1):54–58. Epub 2013 Sep 17.
PubMed Web of Science ®Google Scholar
Fleming P, Roubille C, Richer V, et al. Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. J Eur Acad Dermatol Venereology: JEADV. 2015;29(6):1063–1070. Epub 2014 Dec 11.
PubMed Web of Science ®Google Scholar
McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137–1146. Epub 2015 Jul 03.
Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Interleukin 17-A inhibition in the treatment of psoriasis

References

* This paper reported the results of two phase III randomized controlled trials (UNCOVER-2 and UNCOVER-3), showing the superior efficacy of ixekizumab against etanercept for the treatment of psoriasis at both the primary endpoint of PASI 75 and PASI 90 at week 12.

** This paper reported the results from two phase III clinical trials, AMAGINE-2 and AMAGINE-3, showing brodalumab to have a higher efficacy than ustekinumab for the treatment of psoriasis, using a stringent primary endpoint of PASI 100 at week 12.

** This study, reporting results from the CLEAR randomized controlled trial, showed that secukinumab was superior in efficacy to ustekinumab for the treatment of psoriasis using a primary endpoint of PASI 90 at week 16.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Interleukin 17-A inhibition in the treatment of psoriasis

References

* This paper reported the results of two phase III randomized controlled trials (UNCOVER-2 and UNCOVER-3), showing the superior efficacy of ixekizumab against etanercept for the treatment of psoriasis at both the primary endpoint of PASI 75 and PASI 90 at week 12.

** This paper reported the results from two phase III clinical trials, AMAGINE-2 and AMAGINE-3, showing brodalumab to have a higher efficacy than ustekinumab for the treatment of psoriasis, using a stringent primary endpoint of PASI 100 at week 12.

** This study, reporting results from the CLEAR randomized controlled trial, showed that secukinumab was superior in efficacy to ustekinumab for the treatment of psoriasis using a primary endpoint of PASI 90 at week 16.

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date